SCHEMBL31578340

SCHEMBL31578340

CC1CC(c2cccc(NC(=O)c3cc(CNCC4CCCC4)c4c(n3)C(C)(C)CO4)c2)(c2nncn2C)C1

nearest known ligand 0.59

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ CBLB Q13191 20/20 0.59
▸ CBLC Q9ULV8 2/20 0.45
▸ CBL P22681 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30625489 0.91 CBLB (0.59) CBLBCBLCCBL
SCHEMBL25359067 0.91 CBLB (0.57) CBLBCBLCCBL
SCHEMBL25360450 0.91 CBLB (0.58) CBLBCBLCCBL
SCHEMBL25360711 0.90 CBLB (0.58) CBLBCBLCCBL
SCHEMBL30625494 0.90 CBLB (0.58) CBLBCBLCCBL
SCHEMBL31578250 0.90 CBLB (0.57) CBLBCBLCCBL
SCHEMBL25358551 0.89 CBLB (0.58) CBLBCBLCCBL
SCHEMBL25357725 0.89 CBLB (0.59) CBLBCBLCCBL
SCHEMBL31578351 0.88 CBLB (0.59) CBLBCBLCCBL
SCHEMBL25359636 0.88 CBLB (0.58) CBLBCBLCCBL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163047-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH BEIGENE, LTD. (KY) 2025-05-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163047-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH NFATC1, GZMB, IFNG CBLB 2362/4885CBLC 2283/4885CBL 2661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback